key: cord-0691744-4mm30iyq
authors: Shahani, Pradnya; Datta, Indrani
title: Mesenchymal Stromal Cell therapy for COVID-19: Which? When? And How Much?
date: 2021-04-30
journal: Cytotherapy
DOI: 10.1016/j.jcyt.2021.04.004
sha: a0a0ac732a4c4067302bf09cd16bd8088a75a186
doc_id: 691744
cord_uid: 4mm30iyq

Mesenchymal Stromal Cells (MSCs) are under active consideration as a treatment strategy to control the hyperinflammation and slow disease progression in COVID-19. The possible mechanism of protection through their immunoregulatory and paracrine action has been reviewed extensively. However, the importance of process control to achieve a consistent cell quality, maximum safety and efficacy - for which the three key questions are of ‘which’, ‘when’ and ‘how much’ - remain unaddressed. Any commonality, if exists, in the ongoing clinical trials is yet to be analysed and reviewed. In this review, we have therefore compiled and discussed study design data from ongoing clinical trials to address the key questions of ‘which’ tissue source, donor profile, isolation technique, culture conditions, long-term culture and cryopreservation for MSCs; the question of ‘when’ with regard to defining the transplantation window, by identifying and staging of patients based on their pro-inflammatory profile; and finally that of ‘how much’ with respect to the number of cells in a single administration, the number of doses and route of transplantation. To homogenize MSC therapy for COVID-19 on a global scale and to make it readily available in large numbers, a shared understanding and uniform agreement on these fundamental issues is essential.

I (1) . At stage II, the pulmonary phase of the disease is initiated, mainly featuring shortness of breath. Patients develop pneumonia, with cough, fever, and hypoxia (defined as PaO2/FiO2≤ 300 mm Hg). Lymphopenia is also observed at this stage along with transaminitis. Further, computed tomography of lungs reveals ground glass opacities at this stage like in conventional ARDS. In both COVID-19 and conventional ARDS, bilateral infiltrates are observed (3) . The symptoms of fever, dry cough and shortness of breath too are similar symptoms as reported in conventional ARDS and acute lung injury (ALI). Finally, stage III of the illness manifests as an extrapulmonary systemic hyperinflammation syndrome, with symptoms of ARDS, systemic inflammatory response syndrome/shock, vasoplegia and respiratory and cardiac failure. This severe stage of the illness is however observed in a minority of COVID-19 patients. Systemic multi-organ failure may occur in this advanced stage, similar to secondary hemophagocytic lymphohistiocytosis (4) .

While the mechanisms of pathophysiology remain unclear, the critical role of the immune system in advancing the disease has been well documented (5, 6) . Assessment of these immunopathological features has revealed two key events -1. Direct tropism of SARS-CoV-2 toward ACE2 + epithelial cells of the lungs that results in epithelial cell deathwhich is a "localized" event; and 2. Concurrent increased secretion of IFNs by infected cells as an antiviral defence response, that then stimulates secretion of other pro-inflammatory cytokines. Crucially, SARS-CoV-2 appears capable of disrupting these antiviral inflammatory reactions by blunting type I/III IFN-cytokines, while increasing other proinflammatory cytokines, mainly IL-6 and TNFα (7) , which results in an acute hyperinflammatory response also termed as the "cytokine storm" -this is a "systemic" event.

Wauters et al., 2020 have also presented a compelling model cross-linking these two pathologies and culminating in the classic symptoms of COVID-19 (7) .

While the term "cytokine storm" has been used widely over the last year describing the disease pathophysiology, recent reports have questioned its relevance to the disease. The hyperinflammatory response in COVID-19 has been compared to Cytokine Release Syndrome (CRS)a life threatening toxicity seen in ARDS, CAR-T cell therapy and sepsis (8, 9) . Comparison with previously published data has revealed that while COVID-19 patients present with more than normal plasma IL-6 value, it is 42-, 5-, 85-, and 27-times lower than that of hyperinflammatory ARDS, hypoinflammatory ARDS, CAR-T cell therapy and sepsis, respectively (9) . More so, other pro-inflammatory cytokines -IL8 and TNFα also appear to be significantly lower in severe COVID-19 as opposed to these conditions (9) .

Following this data, the descriptor "cytokine storm" in COVID-19 may be misleading; however, despite its lower intensity, the occurrence of extrapulmonary systemic inflammation seen in COVID-19 is undeniable. Patients with severe COVID-19 typically present with elevated serum levels of pro-inflammatory cytokines and markers -IL-6, TNFα, IL-1β and Creactive protein, in addition to other interleukins that drive hyperinflammation. Additionally, post-mortem analysis of lungs from severe COVID-19 patients has revealed lymphocyte and M1/pro-inflammatory macrophage infiltration that also might cause a hyperinflammatory response (10) .

However, the impact of COVID-19 is not limited to the respiratory system alone. Though it was initially thought to be a severe respiratory disease, several reports of fatalities from multiple organ dysfunction and failure have surfaced (11) . The Angiotensin Converting Enzyme 2 (ACE2) is a component of the renin-angiotensin-aldosterone system (RAAS) which plays a crucial role in controlling blood pressure by maintaining fluid and electrolyte balance in physiological functioning of various organs including heart, vasculature, kidney, adrenal cortex, basal ganglia and brainstem, where it regulates vasoconstriction (6, 11,) .

ACE2 is abundantly expressed on vascular smooth muscle cells, arterial and venous endothelial cells and pericytes, thus facilitating entry for the virus into vasculature (12) . Once the virus gains entry, ACE2 is rendered unavailable to cleave Angiotensin I, thus activating the classical arm of the RAAS pathway resulting in vasoconstriction, fibrosis, oxidative stress and inflammation (6) . Upon infection, endothelial cells undergo apoptosis, disrupt intercellular junctions, and lose contact with the basal membrane, resulting in the loss of integrity of the endothelium. On the other hand, the uncontrolled hyperinflammation also causes endothelial cell activation and a prothrombotic phenotype. Platelet aggregation, vasoconstriction, and increased reactive oxygen species (ROS) generation eventually impair the vascular tone (12) (13) (14) . Consequently, thrombocytopenia, reduced anticoagulants, and blood clots cause disseminated intravascular coagulopathy (DIC) that is observed in severe COVID-19 patients (15, 16) . A key aspect that differs from conventional ARDS and sepsis is the profound coagulopathy the COVID-19 patients suffer from (16) . The ACE2 receptor is extensively expressed in various organsheart, kidneys, lungs, and intestineswhich explains fatalities resulting from blood clots and multi-organ failure. Patients with underlying comorbidities of diabetes and hypertension, or those with immunocompromised conditions, are more likely to experience severe COVID-19 symptoms (17) (18) (19) . Furthermore, a growing number of cases of encephalopathy, ischemic and haemorrhagic stroke are also being reported in COVID-19 and have resulted in higher morbidity and mortality (20, 21) . Elevated C-reactive protein, fibrinogen and D-dimer levels in severe COVID-19 patients are all clinically relevant biomarkers and are indicative of a prothrombotic state and a high probability of developing DIC. Assessment of serum D-dimer levels has proved beneficial in rapidly identifying patients who are at risk of developing DIC or pulmonary thromboembolism and require intense care (22) (23) (24) (25) .

The failure of antiviral drugs has prompted the reorientation of treatment strategies toward reversing the cytokine storm and re-building the host immune system. To achieve this, immunomodulatory drugs (such as corticosteroids, chloroquine and hydroxychloroquine) and

anti-IL 6 antibodies or cytokine blockers (Tocilizumab) have been proposed (26) (27) (28) .

However, as cytokines are pleiotropic, blocking them could hamper the balance of a regulated immune response, resulting in autoimmune effects, tissue damage and a compromised host immune system. Further, cytokine functions have mutual redundancy -the function of a blocked cytokine can be compensated by another (29) . In a recent study, clinical improvement and mortality were statistically comparable between tocilizumab and standard treatment patients in the cohort. Also, the same study found that bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients, suggesting that the IL-6 blocker (tocilizumab) alone is insufficient in controlling the dysregulated immune cascade (30) .

Use of adult Mesenchymal Stromal Cells (MSCs) may be a more effective approach to achieve immunosuppression and immunomodulation. The mechanisms by which MSCs achieve this through their paracrine action or by direct cell-cell contact with immune cells ( Fig. 1 ) have been well established. In summary, MSCs suppress the proliferation and activation of cytotoxic T-cells by release of TGF-β and HGF, resulting in decrease of cyclin D2 and increase of p27kip1 expression in T-cells, thus arresting proliferation in the G1 phase (31) (32) (33) . Further, they induce apoptosis of activated T-cells by the Fas/Fas ligand-dependent pathway, suppress IFN-γ and IL-17 secretion, and promote IL-10 production by inducing the generation of Treg cells (34, 35) . However, these effects can only be achieved when MSCs are pre-stimulated by certain inflammatory cytokines -IFN-γ and TNF-α, IL-1α, or IL-1β. Therefore, transplantation into an inflammatory milieu may actually help in "activating" or "licensing" their immunosuppressive response (36) (37) (38) . In response to stimulation by these inflammatory cytokines, MSCs upregulate their inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2 expression levels, resulting in robust production of nitric oxide (NO) and prostaglandin E2 (PGE2) (39) . Interaction of the inhibitory molecule programmed death 1 (PD-1) with its ligands PD-L1 and PD-L2 has also been demonstrated in the inhibition of T-cell proliferation by MSCs via direct cell-cell contact (40) . Further, MSCs inhibit differentiation of monocytes into dendritic cells (DC) and thus DC maturation, giving rise to immature DCs that render T-cells anergic, in addition to inducing upregulation of antiinflammatory cytokine IL-10 and downregulation of pro-inflammatory cytokines IFN-γ, IL-12, and TNF-α, inducing a more anti-inflammatory DC phenotype (41, 42) . MSCs also suppress proliferation of NK cells, and decrease the secretion of IFN-γ by IL-2-stimulated NK cells. A combination of effects involving cell-to-cell contact and paracrine factors including TGF-β1, PGE-2 and IDO are reported to be responsible for this observation (43) .

MSCs also suppress M1 type macrophages (pro-inflammatory) and induce M2 type (antiinflammatory), which is mediated by secreted PGE-2 (44, 45) .

In addition to above mentioned immunosuppressive mechanisms, MSCs bring about regeneration of damaged tissue by the secretion of a plethora of growth factors. Previous studies in ARDS have demonstrated the capacity of MSCs in lung regeneration through the production of the keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) (46) (47) (48) . MSCs have also been shown to promote the regeneration of ATII cells and contribute to repair of the alveolar-epithelial barrier of ARDS-injured lungs (49) . Additionally, the promotion of alveolar fluid clearance by MSCs has been shown to depend upon claudin-4 that belongs to a family of proteins centrally involved in tight junction formation (50) . Furthermore, MSCs are proven to bring about endothelial cell repair. MSCs secrete VEGF that brings about differentiation of endothelial progenitor cells (EPCs) into endothelial cells (52) . An in vitro study demonstrated that adipose-derived MSC exosomes transferred miR-125a to primary HUVEC cells, enhancing tube formation, increasing tube length and number of branches, and therefore promoting angiogenesis (53) . Another in vitro study showed that an MSC-endothelial cell co-culture significantly reduced endothelial paracellular and transcellular permeability via secretion of HGF in an Acute Lung Injury (ALI) model induced by LPS. The effects were achieved by remodelling of intercellular junctions and increasing proliferation of human pulmonary microvascular endothelial cells (HPMECs) (54) . The allogenic MSC treatment resulted in improved endothelial function three months post transplantation (55) . Based on this preliminary data, MSCs appear to be a strong candidate for treating COVID-19.

MSC therapy for ARDS and ALI: Lessons from the past MSCs have been extensively studiedin vitro, in vivo and in clinical trialsas treatment of conventional ARDS and ALI for the past decade (tabulated in 3, 56, 57) and have been deemed safe to transplant in conventional ARDS. However, ARDS is merely one of the conditions seen in COVID-19one that is to some extent a driver of the pathophysiological state; COVID-19 also appears to be a microvascular or a "blood disease" presented with unusual haematological effects. Brault et al., 2020 compared parameters between moderate to severe ARDS related to COVID-19 and ARDS resulting from other factors (mostly pneumonia and influenza) and observed that dissociation between respiratory mechanics and gas-exchange were comparable between the two groups. About 60% of the COVID-19 cases presented with predominant ground glass opacity with alveolar consolidation (58) . Similar findings in COVID-19 ARDS cases are reported by Haudebourg et al., 2020 too (59) .

ARDS is minimal. Despite these similarities with conventional ARDS, COVID-19 is not limited to the respiratory system alone. As discussed above, a hypercoagulable state is prevalent as evidenced by elevated D-Dimer, thrombin, Tissue Factor V and VIII levels. In addition, the increased production of pro-inflammatory cytokines triggers release of procoagulant mediators and results in platelet aggregation (60) .

Several clinical trials have reported safety of MSC administration in patients with severe ADRS with very few or no infusion related-adverse effects. Of key note is the prospective, double-blind multi-center, randomized trial (START study) wherein 10x10 6 BM-MSCs/kg body weight were transplanted intravenously into 40 ARDS patients. A significant decrease in Ang-2 levels was observed and attributed to reduced inflammation (61) . Another randomized, placebo-controlled, Phase 2a study "MultiStem" evaluated the safety and efficacy of adult BM-MSCs and reported that the MSC treatment was associated with higher number of ventilator-free day score, better Quality of Life outcomes and more importantly, reduced levels of IL-6, IL-1β and IFN-γ 7 days post transplantation (57) .

While these clinical trials have demonstrated safety of MSC therapy in conventional ARDS, safety of intravenous infusions in COVID-19 still remains a challenge owing to the predominant pro-coagulable state. As MSCs express Tissue Factor or CD142 (16) , there is a possibility of exaggerated coagulopathy upon intravenous administration of MSCs during Stage III or the hyperinflammation phase (1) seen in COVID-19. To avoid this, a transplantation window needs to be identified based on a disease staging system keeping in mind simultaneous pulmonary and extrapulmonary manifestations (1) to achieve a favourable risk-benefit ratio.

A pilot study conducted by Leng Z et al, 2020 at Beijing YouAn Hospital, Capital Medical University, China tested the safety and efficacy of intravenous transplantation of ACE2 -MSCs, and showed promising results (the MSC tissue source was not specified). Seven patients (one critically severe, four severe and two common) received a single dose of 1x10 6 cells/kg body weight with or without conventional antipyretic/antiviral treatment and a follow-up period of 14 days. All patients recovered or were discharged within 4-6 days of intervention. The improvement was attributed to reduction in CRP, normalized platelet count, increased levels of regulatory CD4 + T cells and CD14 + CD11c + CD11b mid regulatory dendritic cells, decrease in pro-inflammatory cytokines and increase in IL-10, VEGF, IP-10, and reduction in TNFα. No adverse effects in response to MSC transplantation were reported (62) . Furthermore, the gene expression profile of MSCs showed that they were ACE2and TMPRSS -, suggesting that they could protect themselves from viral attack. Another case report of a severe COVID-19 patient was presented by Liang et al., 2020, wherein three doses of 5x10 7 allogenic UC-MSCs administered intravenously with thymosin-1α at an interval of three days were well tolerated. Serum bilirubin and CRP levels normalized along with an increase in CD3 + , CD4 + and CD8 + up to normal levels. The authors also suggested that the effects were largely due to the immunomodulatory action of UC-MSCs and not thymosin-1α (63) .

These two preliminary studies have caused a snowballing of clinical trials adopting allogenic adult MSCs or its exosomes as an intervention in controlling the progression of COVID-19 ( Table 1) . As of 17 November 2020, 60 clinical trials have been registered at www.clinicaltrials.gov investigating the safety and efficacy of adult allogenic or autologous MSCs for treatment or prevention of COVID-19, with umbilical cord/Wharton"s jelly being the predominant source of cells (38.33%), followed by adipose tissue (16.67%) and the bone marrow (16.67%) ( Fig. 2A) . Other stromal cell sources such as dental pulp (3.33%), placenta (Table 1) .

To homogenize MSC therapy for COVID-19 on a global scale and to make it readily available in large numbers, a uniform understanding with respect to fundamental issues such as the ideal tissue source, ideal time of transplantation of MSCs, route of administration, and the quantum of dosage required, is essential. While a substantial amount of data will indeed be obtained from the results of these clinical trials, making head-to-head comparisons between them will be quite difficult owing to variability in inclusion criteria, tissue source, isolation and culture conditions, and crucially, dosage. As MSCs are biological entities and not chemical drugs, communication between stem cell biologists and clinicians is imperative in taking this approach from bench to bedside. As stem cell biologists, we seek to address these practical issues that are faced, right from selecting donors to transplanting the cells into patients, so as to make MSC therapy available quickly for COVID-19 on a global scale.

The International Society for Cellular Therapy (ISCT) has defined minimal criteria for characterizing MSCs which include the following: (1) plastic adherence in standard culture conditions (2) Positive (95%) for CD105, CD73, CD90 (3) Negative for CD45, CD34, CD14 or CD11b, CD79α or CD19, HLA-DR (4) In vitro differentiation to osteoblasts, adipocytes and chondrocytes (64) . With these basic characterization guidelines in place, SOPs for isolation, expansion, culture and freezing need to be developed in order to standardize the process of obtaining "clinical grade" cells, minimizing differences between manufacturers and batch-to-batch variability.

Adult MSCs can be isolated from several tissue sourcesbone marrow (gold standard; BM-MSCs), umbilical cord or Wharton"s jelly (UC-MSCs or WJ-MSCs), adipose derived tissue (AD-MSCs), dental pulp (DPSCs), peripheral blood, umbilical cord blood, menstrual blood etc. Of the currently registered clinical trials, umbilical cord (or Wharton"s jelly) is the most common source of MSCs and adipose tissue the second most common choice (Table 1) .

While several reports (65) (66) (67) have established the immunomodulatory and regenerative properties of UC/WJ-and AD-MSCs to be at par or better than BM-MSCs (gold standard), we also emphasize their easy availability, ease of isolation, scalability i.e., obtaining high number of cells from comparatively little tissue, as well as the possibility of banking.

Unfortunately, none of the current clinical studies specify the passage number of cells at the time of transplantation. An earlier passage would be a crucial factor in efficacy owing to cell senescence appearing in later passages (68) . Some factors relating to the manufacturing process that contribute to MSC quality and efficacy are discussed below.

Tissue source: The first issue is selecting an optimal source of tissue, by which the highest number of cells of reproducible quality can be obtained at a reasonable cost. Therefore, discarded tissues like umbilical cord (UC) or dental pulp (DP), which are easily accessible, cheaply procured and trigger the fewest ethical concerns, are better choices. However, as the quantity of DP isolated from one tooth is far lesser than the tissue derived from one UC, several teeth may be required to isolate the same number of cells. Furthermore, while bone marrow can yield only 0.001-0.01% of mononuclear cells, adipose tissue can yield 5x10 3

MSCs per gram, and the yield from WJ has been reported to be the highest -1-5x10 4 Donor profile: Once the optimal source of tissue is identified, the next issue to be addressed is the defining of inclusion/exclusion criteria for MSC donors. Several reports have established that donor age is a crucial factor affecting MSC functions. Siegel et al., 2013 reported that BM-MSCs isolated from young female donors were higher in number, had higher proliferation and were more immunosuppressive as compared to older counterparts (74) . Also, age-related decline in adipogenic, osteogenic and neurogenic differentiation potential was observed in BM-MSCs (75) . In addition, diseases like diabetes, obesity and autoimmune disorders are known to influence the stem cell niche and affect endogenous MSC functions (76) (77) (78) (79) . These factors limit our pool and require us to find "perfect control" donors, which could be rare owing to lifestyle choices. WJ-MSCs, being perinatal in origin, Considering the above, we suggest finding a middle ground with respect to the extent of passaging/expansion. Use of cells from passages 3-6 will avoid loss of MSC proliferative ability, replicative senescence and preserve the immunoregulatory efficacy while minimising risk of IBMIR due to TF activation. For this, a higher amount of starting material will of course be required, for which the umbilical cord again appears to be the most appropriate choice.

Another variable in determining the quality of MSC preparations is its cryopreservation. To achieve bedside transplantation, a common practice is to thaw the vial containing a (97) . Another review article extensively details the effect of freeze-thawing on membrane physiology and metabolism of MSCs (93) . Freeze-thawing was reported to affect MSC membrane asymmetry, heat shock protein expression and cytoskeletal aberrations leading to cell shrinkage, cytoplasmic leakage, and apoptotic body formation that are susceptible to increased risk of host immune system recognition and ultimately, attack on infused MSCs (93) . Furthermore, freeze-thawed cells when resuspended in single cell suspensions display hampered aggregation, antigen adsorption and microvascular toxicity and reduced hemocompatibility. On the other hand, some studies have reported restoration of these cellular parameters and functional recovery shortly upon subculture (93) . This data indicates that a restart period could help regain functionality of their physiological processes.

Further investigation using a cryorecovery approach is indicated (93) .

Another significant concern is the cryopreservative used. As we move towards a serumfree/xenofree approach, methods to eliminate the conventional 10% DMSO-90% FBS cryopreservation media are being developed. Also, use of DMSO is a probable reason for impaired MSC membrane physiology and increased vulnerability to complement activation and IBMIR (93) . Grein "procoagulant" MSCs in the "hypercoagulable" COVID-19 condition would be to identify a transplantation window by staging patients based on their pro-inflammatory profile as outlined by Siddiqi and Mehra, 2020 (1). An early transplantation during the pulmonary phase or Stage IIa having moderate pulmonary involvement without hypoxia (1) accompanied with anticoagulants might provide the highest benefit and even slow disease progression. As the inflammation is confined to the lungs at this stage, intravenously administered MSCs will get licenced and assert their regenerative effects locally. An alternative approach could be the use of the intramuscular (IM) route of injection, as it directly avoids the lung vasculature and potentiates MSC dwell time as shown in previous studies (102, 103) . Furthermore, in our previous report we showed that DPSCs transplanted intramuscularly into physiologically healthy, immunocompetent rats migrate to the bone marrow in 24 hours and also overcome the first-pass effect seen in IV, wherein the largersized MSCs are entrapped in lung capillaries resulting in diminished efficacy (104) .

As mentioned above, the 60 clinical trials (Table 1) show extensive variability in their dosage regimens -defined either as "X" million cells per kg body weight or as ballpark numbers like 25, 100 or 300 million cells per dose (irrespective of body weight). To be able to easily compare these dosages, we have calculated each dose (per injection) for an average body weight of 62 kg ( Table 1 ). The most common dose is 1x10 6 cells/kg body weight (i.e., 62x10 6 for a person weighing 62 kg), which has been used in 33.33% of registered trials. Only 8.33%

of the studies employ a dose of 2x10 6 cells/kg i.e., 124x10 6 for a 62 kg person, 10% are using 0.5x10 6 /kg i.e., 31x10 6 cells for 62 kg, while 18.33% are injecting 100x10 6 cells irrespective of body weight. 16.66% of these trials are using doses below 100x10 6 cells ranging from 20x10 6 to 99x10 6 . On the other hand, 6.66% have adopted higher numbers ranging from 200x10 6 to 400x10 6 per dose (Table 1 ). In addition to variation in number of cells per dose, differences are also observed in frequency of injections (Fig. 2B) . A single or three repeat doses are the most common, being performed by 16 studies each. 13 of the 60 studies have chosen two repeat doses, while 5 and 2 studies have chosen four or five repeat doses, respectively ( Fig 2B) . Furthermore, interval between repeat injections differs from 24 hours to 28 days (i.e., 672 hours; Table 1 remodelling as compared to a single or two doses (108) . In our previous study, we too have shown that two doses of 1x10 6 DP-MSCs administered intramuscularly into a rat model of diabetic neuropathy not only resulted in significant reduction of systemic inflammation, improved nerve conduction velocity and reduced pain, but also suggested that the second dose was essential to maintain the improved state (109) .

As far as the interval between repeated MSC administrations is concerned, the clearance rate of MSCs from the body can serve as a reference point for the next dose. However, this can only be determined using biodistribution studies. By now it is well established that intravenously transplanted MSCs first reach the lungs and then migrate to sites of inflammation. For example, Gholamrezanezhad et al. showed that intravenously transplanted BM-MSCs in patients with advanced liver cirrhosis migrated to the liver and spleen by the 10th day post-infusion (110). As systemic inflammation and organ damage is observed in COVID-19 too, the expectation is that transplanted MSCs will migrate to these sites and/or assert their regenerative effects via paracrine or direct cell-to-cell mediated mechanisms.

Again, more definitive answers to this question can be obtained only through biodistribution experiments.

The last few months have seen a rapid emergence of MSC therapy for COVID-19. While investigators at academic institutes and at eminent manufacturers like Mesoblast, Athersys, Pluristem and CellaVita are extensively involved in these studies, a scientific consensus with respect to quality, design, dosage and administration schedules for MSCs is yet to emerge. In order to minimize these inconsistencies, we propose that standardized protocols be established through a global consortium network. At the very least, existing regulatory bodies should consider coming together to establish a single unified protocol for fast-tracking the use of MSCs and making it available on a larger scale.

We also urge all MSC manufacturers to come forward and take the lead in making COVID-19 treatment widely available through their resources or existing MSC biobanks. A starting point for this would be a standardization of the production process and source protocols. In a recent review, Dr. Mark Pittenger has rightly stated that "the MSC process is the MSC product", underlining the importance of process control for achieving a consistent quality (111) . In this review, we have emphasised not just the immunomodulatory and regenerative effects of WJ-MSCs, but also their easy availability and potential for up-scaling.

Furthermore, we have discussed three other critical points of concernquality of MSCs i.e., culture conditions, time of administration, and dosage; of which most important is screening of TF/CD142 expression along with standard immunophenotyping that needs to be integrated into the design of clinical trials.

The scientific community has conducted basic and clinical research on MSCs in many disease conditions for more than twenty years now, and has already established their immunomodulatory and regenerative effects in COVID-19. Utilizing MSCs for COVID-19

will not only help in treating this disease, but may also change the face of MSC therapy in other inflammatory and degenerative conditions. 

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study

COVID-19 and the reninangiotensin system (RAS): A spark that sets the forest alight?

Establishing a Unified COVID-19 "Immunome": Integrating Coronavirus Pathogenesis and Host Immunopathology

Is a "Cytokine Storm" Relevant to COVID-19?

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. The Lancet. Respiratory medicine

Immunopathology of Hyperinflammation in COVID-19. The American journal of pathology

Extrapulmonary manifestations of COVID-19

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? The European respiratory journal

Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses

Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science

COVID-19 and its implications for thrombosis and anticoagulation

MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy

Severe COVID-19: what have we learned with the immunopathogenesis?

How Do Inflammatory Mediators, Immune Response and Air Pollution Contribute to COVID-19 Disease Severity? A Lesson to Learn

A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic

Neurological associations of COVID-19

COVID-19-related strokes are associated with increased mortality and morbidity: A multicenter comparative study from Bengaluru, South India. International journal of stroke : official journal of the International Stroke Society, 1747493020968236

COVID-19: towards understanding of pathogenesis

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

COVID-19: immunopathology and its implications for therapy

D-Dimer Concentrations and COVID-19 Severity: A Systematic Review and Meta-Analysis. Frontiers in public health

Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Cytokine-targeted therapy in severely ill COVID-19 patients: Options and cautions

Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations

Efficacy and safety of tocilizumab in severe COVID-19 patients: a singlecentre retrospective cohort study

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells

Mesenchymal stem cells inhibit T cell activation by releasing TGF-β1 from TGF-β1/GARP complex

Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis

Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs

Mesenchymal stromal cell 'licensing': a multistep process

Interactions between mesenchymal stem cells and the immune system

Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application

Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies

Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cellular and molecular life sciences: CMLS

Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle

Secretion of immunoregulatory cytokines by mesenchymal stem cells

NK Cells and MSCs: Possible Implications for MSC Therapy in Renal Transplantation

Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages

Human Mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE 2 -dependent mechanism

Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung

The Vascular Endothelial Growth Factors-Expressing Character of Mesenchymal Stem Cells Plays a Positive Role in Treatment of Acute Lung Injury In Vivo

The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo

Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives

Protective effect of bone marrow derived mesenchymal stem cells in lipopolysaccharide-induced acute lung injury mediated by claudin-4 in a rat model

Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment

VEGF secreted by mesenchymal stem cells mediates the differentiation of endothelial progenitor cells into endothelial cells via paracrine mechanisms

Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a

Interaction between mesenchymal stem cells and endothelial cells restores endothelial permeability via paracrine hepatocyte growth factor in vitro

Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells

Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

Rationale for the clinical use of adiposederived mesenchymal stem cells for COVID-19 patients

COVID-19-versus non-COVID-19-related Acute Respiratory Distress Syndrome: Differences and Similarities. American journal of respiratory and critical care medicine

Respiratory Mechanics of COVID-19-versus Non-COVID-19-associated Acute Respiratory Distress Syndrome

Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Transplantation of ACE2 -Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues

Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells

Bone marrow vs Wharton's jelly mesenchymal stem cells in experimental sepsis: a comparative study

Replicative senescence of mesenchymal stem cells: a continuous and organized process

Wharton's jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance

Tissue factor, blood coagulation, and beyond: an overview

Are therapeutic human mesenchymal stromal cells compatible with human blood

Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines

Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application

Phenotype, donor age and gender affect function of human bone marrowderived mesenchymal stromal cells

Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells

Intrinsic Mesenchymal Stem Cell Dysfunction in Diabetes Mellitus: Implications for Autologous Cell Therapy

Dysfunction of Mesenchymal Stem Cells Isolated from Metabolic Syndrome and Type 2 Diabetic Patients as Result of Oxidative Stress and Autophagy may Limit Their Potential Therapeutic Use

Challenges and Controversies in Human Mesenchymal Stem Cell Therapy

Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. Cellular and molecular life sciences: CMLS, 1-21

Comparison of explant-derived and enzymatic digestion-derived MSCs and the growth factors from Wharton's jelly

Addressing the impact of different fetal bovine serum percentages on mesenchymal stem cells biological performance

A plea to reduce or replace fetal bovine serum in cell culture media

A consensus introduction to serum replacements and serumfree media for cellular therapies

Xeno-Free Strategies for Safe Human Mesenchymal Stem/Stromal Cell Expansion: Supplements and Coatings

Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media

Are serum-free and xenofree culture conditions ideal for large scale clinical grade expansion of Wharton's jelly derived mesenchymal stem cells? A comparative study

Proliferation, Characterization and Differentiation Potency of Adipose Tissue-Derived Mesenchymal Stem Cells (AT-MSCs) Cultured in Fresh Frozen and non-Fresh Frozen Plasma

The Dynamics of Cell Properties during Long-Term Cultivation of Two Lines of Mesenchymal Stem Cells Derived from

Wharton"s Jelly of Human Umbilical Cord

Comparison of biological properties of umbilical cord-derived mesenchymal stem cells from early and late passages: immunomodulatory ability is enhanced in aged cells

Cell senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia model

Gene expression profile of immunoregulatory cytokines secreted from bone marrow and adipose derived human mesenchymal stem cells in early and late passages

Aging of bone marrow-and umbilical cord-derived mesenchymal stromal cells during expansion

Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy

The Utilization of Freezing Steps in Mesenchymal Stromal Cell (MSC) Manufacturing: Potential Impact on Quality and Cell Functionality Attributes

The impact of cryopreservation on bone marrow-derived mesenchymal stem cells: a systematic review

Effects of cryopreservation and long-term culture on biological characteristics and proteomic profiles of human umbilical cord-derived mesenchymal stem cells

Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties

Alternatives to dimethylsulfoxide for serum-free cryopreservation of human mesenchymal stem cells

Cryopreservation of Human Wharton's Jellyderived Mesenchymal Stem Cells Following Controlled Rate Freezing Protocol Using Different Cryoprotectants; A Comparative Study

Procoagulant activity of human mesenchymal stem cells. The journal of trauma and acute care surgery

Selection of Tissue Factor-Deficient Cell Transplants as a Novel Strategy for Improving Hemocompatibility of Human Bone Marrow Stromal Cells

Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes

Concise Review: Skeletal Muscle as a Delivery Route for Mesenchymal Stromal Cells

Biodistribution of Intramuscularly-Transplanted Human Dental Pulp Stem Cells in Immunocompetent Healthy Rats through NIR Imaging

COVID-19 pneumonia

Mesenchymal stem cells as therapeutics

Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range? Stem cells translational medicine

Multiple doses of adipose tissue-derived mesenchymal stromal cells induce immunosuppression in experimental asthma

Functional recovery upon human dental pulp stem cell transplantation in a diabetic neuropathy rat model

In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis

Mesenchymal stem cell perspective: cell biology to clinical progress

Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review